Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Deubiquitinase that antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by mediating deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting S phase entry.
Showing 10 out of 37 products:
Human Polyclonal USP37 Primary Antibody for ICC, IF - ABIN258290
Das, Taylor, Gireud, Singh, Lee, Fuller, Ji, Fangusaro, Rajaram, Goldman, Eberhart, Gopalakrishnan: The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation. in Oncogene 2013
Human Polyclonal USP37 Primary Antibody for ICC, IF - ABIN4364592
Stadler, Rexhepaj, Singan, Murphy, Pepperkok, Uhlén, Simpson, Lundberg: Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells. in Nature methods 2013
these findings reveal a role for REST-associated G9a (show EHMT2 Antibodies) and histone H3K9 methylation in the repression of USP37 expression in medulloblastoma. Reactivation of USP37 by G9a (show EHMT2 Antibodies) inhibition has the potential for therapeutic applications in REST-expressing medulloblastomas
USP37 interacts with Cdt1 (show CDT1 Antibodies) and is able to de-ubiquitinate Cdt1 (show CDT1 Antibodies) in vivo and, USP37 is able to regulate the loading of MCM complexes onto the chromatin.
USP37 associates with cohesin and contributes to sister chromatid resolution. Cohesion defects are rescued by expression of an RNAi-resistant USP37, but not the catalytically impaired USP37(C350A) mutant.
USP37 is significantly upregulated in human lung cancer tissues, where its expression is positively correlated with c-Myc (show MYC Antibodies) protein expression.
These results suggested that the UIMs in USP37 contribute to the full enzymatic activity, but not ubiquitin chain substrate specificity, of USP37 possibly by holding the ubiquitin chain substrate in the proximity of the catalytic core.
our findings of USP37-modulating PLZF (show ZBTB16 Antibodies)/RARA (show RARA Antibodies) stability and cell transformation suggest that USP37 is a potential therapeutic target for PLZF (show ZBTB16 Antibodies)/RARA (show RARA Antibodies)-associated APL (show FASL Antibodies)
USP37 links REST to the control of p27 (show PAK2 Antibodies) stability and cell proliferation.
Skp1 (show SKP1 Antibodies)-Cul1 (show CUL1 Antibodies)-F-box ubiquitin ligase (SCF (show KITLG Antibodies)(betaTrCP (show BTRC Antibodies)))-mediated destruction of the ubiquitin-specific protease USP37 during G2-phase promotes mitotic entry
The deubiquitinase USP37 binds CDH1 (show CDH1 Antibodies) and removes degradative polyubiquitin (show UBB Antibodies) from cyclin A (show CCNA2 Antibodies). USP37 was induced by E2F (show E2F1 Antibodies) factors in G1, peaked at G1/S, and was degraded in late mitosis. Phosphorylation of USP37 by CDK2 (show CDK2 Antibodies) stimulated its full activity.
Deubiquitinase that antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by mediating deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting S phase entry. Specifically mediates deubiquitination of 'Lys-11'- linked polyubiquitin chains, a specific ubiquitin-linkage type mediated by the APC/C complex. Also mediates deubiquitination of 'Lys-48'-linked polyubiquitin chains in vitro. Phosphorylation at Ser-630 during G1/S phase maximizes the deubiquitinase activity, leading to prevent degradation of cyclin-A (CCNA1 and CCNA2) (By similarity).
ubiquitin specific peptidase 37
, ubiquitin specific protease 37
, ubiquitin carboxyl-terminal hydrolase 37-like
, deubiquitinating enzyme 37
, ubiquitin carboxyl-terminal hydrolase 37
, ubiquitin thioesterase 37
, ubiquitin thiolesterase 37
, ubiquitin-specific-processing protease 37
, Deubiquitinating enzyme 37
, Ubiquitin carboxyl-terminal hydrolase 37
, Ubiquitin thiolesterase 37
, Ubiquitin-specific-processing protease 37